Arrowstreet Capital Limited Partnership Has $301.65 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Arrowstreet Capital Limited Partnership boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 185.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 674,495 shares of the medical equipment provider’s stock after purchasing an additional 438,200 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.19% of Intuitive Surgical worth $301,654,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Tobam lifted its position in shares of Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 40 shares during the last quarter. Kilter Group LLC bought a new position in Intuitive Surgical in the second quarter valued at about $27,000. Greykasell Wealth Strategies Inc. acquired a new position in Intuitive Surgical during the third quarter worth about $27,000. Caitlin John LLC bought a new position in shares of Intuitive Surgical in the third quarter worth about $30,000. Finally, Guerra Advisors Inc acquired a new stake in shares of Intuitive Surgical in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 2.8%

Shares of Intuitive Surgical stock opened at $479.27 on Friday. The stock has a market cap of $170.20 billion, a price-to-earnings ratio of 60.74, a P/E/G ratio of 3.80 and a beta of 1.66. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $603.88. The company’s fifty day moving average is $515.05 and its 200 day moving average is $512.37.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same period in the previous year, the business earned $2.21 EPS. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Mark Brosius sold 645 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the sale, the senior vice president owned 1,613 shares in the company, valued at $782,321.13. This represents a 28.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Fredrik Widman sold 133 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total value of $65,829.68. Following the sale, the vice president directly owned 660 shares of the company’s stock, valued at $326,673.60. This represents a 16.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 33,407 shares of company stock worth $17,534,067. 0.70% of the stock is owned by insiders.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Citi upgraded ISRG to Buy with a $590 target, which boosts near‑term sentiment and signals analyst confidence in upside. Citigroup upgrades Intuitive Surgical (ISRG)
• Positive Sentiment: The da Vinci system won FDA clearance for cardiac surgery, opening a much larger TAM (from ~17k to ~160k potential procedures in cleared markets) — a material long‑term growth catalyst if adoption follows. ISRG’s da Vinci Gains FDA Nod for Cardiac Surgery
• Positive Sentiment: Q4 results beat expectations (19% revenue growth, EPS beat) and management highlighted recurring revenue strength — these prints underpin the bullish analyst commentary and recent outperformance days. Intuitive Surgical Inc. stock outperforms competitors
• Neutral Sentiment: Long‑form bulls argue “massive growth ahead” from da Vinci 5, Ion and SP platforms — supportive for the multi‑year case but not a near‑term catalyst. Intuitive Surgical: The Robotic Surgery Leader Still Has Massive Growth Ahead
• Neutral Sentiment: Several valuation pieces note ISRG trades well above historical P/E levels, creating a tension between growth expectations and an elevated multiple — keeps the stock range‑bound absent fresh catalysts. Assessing Intuitive Surgical (ISRG) Valuation
• Negative Sentiment: Management guided for a deceleration in worldwide da Vinci procedure growth in 2026 — a notable near‑term headwind to growth expectations. Intuitive Surgical Stock: Buy, Sell, or Hold?
• Negative Sentiment: Insider selling (multiple senior exec trades in March) is visible and may be fueling profit‑taking and downside pressure despite strong public messaging. SEC filing: Insider Sale Disclosures
• Negative Sentiment: Stock has recently fallen more than the market on low‑volume sessions, indicating short‑term technical weakness and profit‑taking after the post‑earnings run. Intuitive Surgical Suffers a Larger Drop Than the General Market

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ISRG shares. HSBC lifted their price target on shares of Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a report on Monday, January 26th. Raymond James Financial boosted their target price on shares of Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. The Goldman Sachs Group reiterated a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a report on Friday, January 9th. Truist Financial increased their price target on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Evercore reduced their price objective on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating on the stock in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $615.86.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.